TMOD1

Across TCGA pan-cancer cohorts, TMOD1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMOD1 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TMOD1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMOD1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where TMOD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.552	0.215	<.001	49	view →
CCRCC	DFS	Median	All	0.876	0.617	<.001	27	view →
LUAD	DFS	Tertile	III,IV	0.311	0.995	.001	19	view →
LSCC	DFS	Quartile	II,III,IV	0.831	0.310	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMOD1–PDAC (DFS)

Open the PDAC breakdown →